Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 148.0371
25 292.5063
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Relative Value
The Relative Value of one
LALPATHLAB
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 1 376.4 INR,
Dr. Lal PathLabs Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
LALPATHLAB Competitors Multiples
Dr. Lal PathLabs Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
226.9B INR | 8.7 | 42.4 | 29 | 36.2 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
104.7B USD | 0.3 | 223.2 | 14.4 | 14.4 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
63.4B EUR | 0.3 | 12.1 | 9.1 | 11.6 | |
| US |
|
Cigna Corp
NYSE:CI
|
74.2B USD | 0.3 | 12.1 | 0 | 0 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
27.2B EUR | 1.2 | 23.9 | 10.4 | 15.8 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
21.9B EUR | 1.1 | 30.5 | 9.8 | 20.9 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22B USD | 1.6 | 25.8 | 13.9 | 19.5 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
20B USD | 1.8 | 20.8 | 11.5 | 15.5 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
14.5B USD | 16 | -36.2 | -38.1 | -34.5 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 0.6 | 15.1 | 6.1 | 13 | |
| US |
|
DaVita Inc
NYSE:DVA
|
7.6B USD | 0.6 | 9.9 | 6.5 | 8.8 |
